WEE-family kinases in cancer: synthetic lethal interactions and drug discovery

Area of Science:

• Molecular Biology
• Cancer Therapeutics
• Cell Cycle Regulation

Background:

• WEE1 and PKMYT1 kinases are crucial for the G2/M cell cycle checkpoint, maintaining genomic stability.
• Cancer cells with DNA damage response (DDR) deficiencies exhibit synthetic lethality when WEE1/PKMYT1 are inhibited.
• This vulnerability presents a promising therapeutic strategy for specific cancer types.

Purpose of the Study:

• To review the mechanistic basis of synthetic lethality involving WEE1 and PKMYT1 in DDR-deficient cancers.
• To highlight advances in selective WEE kinase inhibitors and their therapeutic potential.
• To discuss challenges and future strategies for developing WEE kinase inhibitors.

Main Methods:

• Review of preclinical and clinical studies on WEE1 and PKMYT1 inhibitors.
• Analysis of the synthetic lethality mechanism in the context of DDR deficiencies.
• Examination of recent developments in selective WEE kinase inhibitor design and evaluation.

Main Results:

• Next-generation WEE1 inhibitors show improved safety and efficacy in clinical trials.
• PKMYT1 inhibitors are emerging as a complementary therapeutic approach.
• Targeted inhibition of WEE1/PKMYT1 selectively induces genomic instability in cancer cells.

Conclusions:

• Targeting WEE1 and PKMYT1 offers a promising strategy for DDR-deficient cancers.
• Selective WEE kinase inhibitors are advancing, but challenges remain.
• Further research is needed to optimize inhibitor development and clinical application.